Quick ratio of Coherus BioSciences, Inc.
The quick ratio is the ratio between quick or liquid assets and current liabilities. Quick assets include those current assets that presumably can be quickly converted to cash at close to their book values. A normal liquid ratio is considered to be 1. A company with a quick ratio of less than 1 cannot at the time fully pay its current liabilities or short-term obligations. This ratio is considered to be a much reliable tool for assessment of liquidity position of companies.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non?small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
|MTNB Matinas Biopharma Holdings, Inc.||NYSEMKT > Health Care > Major Pharmaceuticals||5.40|
|CFMS ConforMIS, Inc.||NASDAQ > Health Care > Industrial Specialties||5.41|
|NRE NorthStar Realty Europe Corp.||NYSE > Consumer Services > Real Estate Investment Trusts||5.42|
|TIF Tiffany & Co.||NYSE > Consumer Services > Consumer Specialties||5.44|
|LGL LGL Group, Inc. (The)||NYSEMKT > Capital Goods > Industrial Machinery/Components||5.44|
|NANO Nanometrics Incorporated||NASDAQ > Capital Goods > Industrial Machinery/Components||5.45|
|CHRS Coherus BioSciences, Inc.||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||5.46|
|MAG MAG Silver Corporation||NYSEMKT > Basic Industries > Precious Metals||297.63|
|ORI Old Republic International Corporation||NYSE > Finance > Property-Casualty Insurers||762.43|
|WMIH WMIH Corp.||NASDAQ > Finance > Finance: Consumer Services||812.31|
|AMG Affiliated Managers Group, Inc.||NYSE > Finance > Investment Managers||966.10|
|HUNT Hunter Maritime Acquisition Corp.||NASDAQ > Transportation > Oil Refining/Marketing||1,687.50|
|IOR Income Opportunity Realty Investors, Inc.||NYSEMKT > Consumer Services > Real Estate Investment Trusts||4,830.80|